Invivyd (NASDAQ: IVVD) — Company Overview, News & Financial Data
Invivyd is a biotechnology company developing antibody solutions for infectious diseases and focusing on patient outcomes.
Invivyd
Invivyd (NASDAQ:IVVD) is a biotechnology company focused on developing innovative solutions to combat infectious diseases, with a particular emphasis on antibodies designed to prevent and treat various viral infections. Their operations span from early-stage research to advanced clinical trials, aiming to address the unmet medical needs in the infectious disease space. Invivyd's projects include developing therapies that could provide immediate and long-term immunity against challenging viruses, leveraging cutting-edge technology and scientific research. The company's objectives are centered around delivering high-impact solutions to global health threats, fostering partnerships with leading health organizations, and ultimately, improving patient outcomes through the power of immunology and biotechnology innovations.
Snapshot
Operations
Products and/or services of Invivyd
- Development of antibody therapeutics targeting infectious diseases.
- Advancements in the prevention and treatment of HIV.
- Research on monoclonal antibodies for COVID-19 prophylaxis and treatment.
- Pipeline of products aimed at combating respiratory syncytial virus (RSV).
- Innovations in biotechnology to enhance drug delivery mechanisms.
- Collaboration on global health initiatives for vaccine-preventable diseases.
Invivyd executive team
- Marc William EliaCEO & Chairperson of the Board
- William E. Duke Jr.CFO and Principal Financial & Accounting Officer
- Jill AndersenChief Legal Officer & Corporate Secretary
- Timothy LeeChief Commercial Officer
- Robert D. AllenChief Scientific Officer
- Kristie Coneys KuhlChief Communications Officer
- Julie GreenChief Human Resources Officer
- Rachael GerlachSenior Vice President of Regulatory Affairs
- Katie FalzoneSenior Vice President of Finance
- Michael J. MinaChief Medical Officer & Chief Epidemiologist
Latest news about Invivyd
Invivyd reports Phase 3 VYD2311 COVID-19 trial results
United StatesInvivyd receives regulatory termination notice for covid antibody
United StatesInvivyd completes phase 3 trial enrollment
United StatesInvivyd doses first participants in phase 3 COVID-19 study evaluating antibody-vaccine co-administration
United StatesInvivyd finishes late-stage enrollment for upsized covid antibody study
United StatesInvivyd revenue grows 22% as company shifts focus to next-gen COVID antibody
United States
Key financials
Reported results for Invivyd, in USD.
- Market cap
- 171.5M
- Revenue (TTM)
- 58.4M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.3
- Dividend yield
- —
- Profit margin
- -183.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 53.4M | -55.6M | -52.5M | |
| 25.4M | -176.9M | -169.9M | |
| 0 | -212.8M | -198.6M | |
| 0 | -248M | -241.3M |